Medicare Part D Now Covers GLP-1 Medications for Obesity Without Diabetes
GLP-1 Authority Editorial Team
Medical News Desk
CMS finalized a rule expanding Medicare Part D coverage for GLP-1 receptor agonists prescribed for obesity, regardless of diabetes status, potentially benefiting 3.4 million beneficiaries starting January 2027.
Key Points
- CMS finalized Medicare Part D coverage for GLP-1 medications for obesity starting January 2027
- Coverage applies regardless of diabetes status — a major policy shift
- Estimated 3.4 million Medicare beneficiaries with obesity may now qualify
- Prior authorization will still be required; coverage criteria vary by plan
- Projected federal cost: $35 billion over 10 years, offset by reduced cardiovascular events
A Landmark Policy Change
The Centers for Medicare and Medicaid Services (CMS) has finalized a rule that will expand Medicare Part D coverage to include GLP-1 receptor agonists prescribed for obesity, regardless of whether the patient has type 2 diabetes. This represents a significant policy reversal — previously, Medicare Part D could only cover GLP-1 medications when prescribed for diabetes, not for obesity alone. The new coverage takes effect January 1, 2027.
Who Will Benefit?
CMS estimates that approximately 3.4 million Medicare beneficiaries with obesity (BMI 30 or higher) or overweight with at least one weight-related comorbidity (hypertension, dyslipidemia, cardiovascular disease, or obstructive sleep apnea) who do not have type 2 diabetes will become newly eligible for GLP-1 coverage under Part D. This is in addition to the millions of Medicare beneficiaries with diabetes who already have access to GLP-1 medications.
Coverage Details and Prior Authorization
While the rule mandates that Part D plans cover at least one GLP-1 medication for obesity, the specific drugs covered, tier placement, and cost-sharing will vary by plan. Prior authorization will still be required, and plans may impose step therapy requirements (e.g., requiring a trial of lifestyle intervention before approving GLP-1 therapy). Beneficiaries should check their specific plan's formulary and contact their plan for coverage details.
Cost Implications
The Congressional Budget Office estimates the expanded coverage will cost the federal government approximately $35 billion over 10 years. However, proponents argue that this cost will be partially offset by reductions in cardiovascular events, hospitalizations, and other obesity-related complications. The SELECT trial demonstrated that semaglutide reduces cardiovascular events by 20%, and cardiovascular disease is the leading cause of death and hospitalization in Medicare beneficiaries.
What This Means for Patients
If you are a Medicare beneficiary with obesity who has been unable to access GLP-1 medications due to cost, this policy change may significantly reduce your out-of-pocket expenses starting in 2027. Under the Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D, your maximum annual cost for GLP-1 medications would be $2,000, compared to the $16,000 or more annual list price without insurance. Contact your Medicare plan or a Medicare counselor for personalized guidance.
State Medicaid Programs
Several states have already expanded Medicaid coverage for GLP-1 medications for obesity, including California, New York, and Massachusetts. Other states are expected to follow the federal Medicare lead. If you are on Medicaid, contact your state's Medicaid program to determine current coverage for GLP-1 medications for obesity.
Medical Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting, stopping, or changing any medication.